Intravenous Immunoglobulin Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2021 to 2027

Rise in prevalence of autoimmune disorders across the globe and surge in demand for intravenous immunoglobulin for treating neurological disorders supplement the growth of the intravenous immunoglobulin (IVIG) market.

The global intravenous immunoglobulin market was valued at $8,995 million in 2017, and is projected to reach $15,964 million by 2027, registering a CAGR of 7.5% from 2018 to 2027. Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to antigens, which are foreign to the host system. They are highly complex entities and specific in their action.

Download Free Sample Report @

https://www.alliedmarketresearch.com/request-sample/325

The global IVIG market is driven by factors such as high prevalence of diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia coupled with surge in geriatric population and rise in the number of hemophilic patients. In addition, increase in production of immunoglobulin with better plasma quality using advanced purification techniques is expected to supplement the market growth. On the other hand, technological advancements in IVIG products are anticipated to provide lucrative opportunities in the market in near future. However, stringent government regulations towards IVIG products and side effects associated with the use of IVIG impede the growth of the market.

Based on application segment, hypogammaglobulinemia held the largest market share in 2017, and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.

Myasthenia gravis segment to grow the fastest through 2027

Among applications, the myasthenia gravis segment is projected to grow at the fastest CAGR of 10.1% from 2018 to 2027, owing to significant rise in the incidence of this disease. At present, there are nearly 60,000 cases of this disease in the U.S. The prevalence of the disease is expected to grow in future, which needs treatment using IVIG. The hypogammaglobulinemia segment occupied more than one-fifth share of the global market in 2017 and is expected to continue its dominance throughout the forecast period of 2018-2022. The report also analyses segments such as chronic inflammatory demyelinating polyneuropathy, immunodeficiency disease, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others.

Key Findings of the Intravenous Immunoglobulin (IVIG) Market:
Myasthenia gravis segment is projected to grow at the highest rate during the forecast period.
Hypogammaglobulinemia was the largest revenue contributor in 2017 and is expected to continue its dominance throughout the forecast period.
North America dominated the global intravenous immunoglobulin market in 2017.

Inquiry for Buying @

https://www.alliedmarketresearch.com/purchase-enquiry/325

LAMEA is estimated to grow at the highest CAGR of 10.3% from 2018-2025.

In 2017, North America accounted for the largest share in the global market, followed by Asia-Pacific. The major factors responsible for the growth of the intravenous market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. coupled with the presence of large plasma production facilities.

The key companies profiled in the report include Baxter International Inc., CSL Ltd., Grifols, S.A., Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, and Bayer AG. The other players included in the value chain analysis (but not included in the report) are Omrix Biopharmaceuticals Ltd.; Behring GmbH; Shanghai RAAS Blood Products Co., Ltd.; Option Care Enterprises, Inc.; ADMA Biologics, Inc.; and BioScrip, Inc.

Read More:

https://www.alliedmarketresearch.com/intravenous-immunoglobulin-ivig-market

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.